Dobutamine Stress Echocardiography in

2

1

Low-Gradient Aortic Stenosis

3

- Nils Sofus Borg Mogensen, MD^{1,2,3}, Mulham Ali, MD^{1,3}, Rasmus Carter-Storch, MD, Ph.D¹, Mohamed-Salah
 Annabi, MD², Jasmine Grenier-Delaney, MD², Jacob Eifer Møller, MD, Ph.D, DMSCi^{1,4}, Kristian Altern
- 7 Øvrehus MD, PhD¹, Patricia A Pellikka, MD⁵, Philippe Pibarot DVM, PhD², Marie-Annick Clavel DVM, PhD^{2,3},
- 8 Jordi Sanchez Dahl MD, PhD, DMSCi^{1,3}
- 9
- 10
- ¹**Department of Cardiology**, Odense University Hospital, Odense, Denmark.
- 12 ² Institut Universitaire de Cardiologie et de Pneumologie de Québec (Québec Heart and Lung Institute),
- 13 Laval University, Québec, Québec, Canada.
- 14 ³ Clinical Institute, University of Southern Denmark, Odense, Denmark.
- ⁴ **Department of Cardiology**, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
- ⁵ Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
- 17
- 18
- 19
- 20
- 21 Corresponding author:
- 22 Nils Sofus Borg Mogensen, MD
- 23 Nils.Sofus.Borg.Mogensen@rsyd.dk
- 24 Nørregade 54, 01 TV, 5000 Odense C
- 25 Denmark
- 26 Word count: 3.666
- 27

28 Abstract

29	Background: Dobutamine stress echocardiography (DSE) is recommended by guidelines to distinguish
30	between true-severe and pseudo-severe aortic stenosis (AS) in patients with low-gradients and left
31	ventricular ejection fraction (LVEF) <50%. However, DSE has mostly been tested in the setting of LVEF<35%
32	and determination of AS severity has mostly been based on outcome data and surgeon's evaluation. The
33	purpose of this study was to examine the diagnostic accuracy of guideline recommendations for DSE, in
34	patents with low-gradient severe AS with a wide range of LVEF and to examine the interaction between the
35	diagnostic accuracy of DSE and LVEF. Furthermore, we wanted to study the safety and feasibility of DSE in
36	patients with LVEF>50%.
37	Methods: Patients with aortic mean gradient <40 mmHg, AVA <1.0 cm ² , and stroke volume index ≤35
38	mL/m ² undergoing DSE and Cardiac Computer Tomography (C-CT) were identified from three prospectively
39	collected patient cohorts, and stratified according to LVEF; LVEF <35%, LVEF 35-50% & LVEF >50%. Severe
40	AS was defined as AVC score ≥2000 AU among men, and ≥1200 AU for women on C-CT.
41	Results: Two hundred twenty-one patients were included in the study. Seventy-eight (35%) presented with
42	LVEF <35%, 67 (30%) with LVEF 35-50%, and 76 (34%) with LVEF >50%. DSE was performed without adverse
43	symptoms or significant arrhythmias in 215 (96%) patients and stroke volume increased uniformly with no
44	significant differences between groups (p=0.28).
45	Mean gradient and V_{max} during DSE showed significantly diagnostic heterogeneity between LVEF groups,
46	being most precise when LVEF <35% (both AUC=0.90), albeit with optimal thresholds of 30 mmHg & 377
47	cm/s, and a limited diagnostic yield in patients with LVEF≥35% (AUC=0.67 in LVEF 35-50% and AUC 0.65 in
48	LVEF≥35%). Using guideline thresholds led to a sensitivity and specificity of 49%/84% for all patients with
49	LVEF <50%.
50	Conclusion: While DSE is safe and leads to a uniform increase in stroke volume in patients with low
51	gradient AS regardless of baseline LVEF, the association between DSE gradients and AS severity assessed by

- 52 C-CT demonstrates important heterogeneity depending on LVEF, with highest accuracy in patients with
- 53 LVEF <35%.
- 54
- 55 Clinical perspective
- 56 What is new?
- Dobutamine stress echocardiography (DSE) is safe in patients with low-gradient AS with LVEF >50%,
- 58 and leads to similar increase in stroke volume as in patients with LVEF <50%.
- The diagnostic accuracy of DSE, compared to AVC as the reference for severe AS, depends on LVEF
- 60 with highest accuracy in patients with LVEF <35%.
- Suggested reference thresholds for DSE may not be the most accurate for AS severity, when
- 62 compared to AVC.
- 63 What are the clinical implications?
- Based on our study, we suggest that DSE should primarily be used for determining AS severity in
- 65 patients with LVEF <35%.

- 66 Non-standard abbreviations and acronyms:
- 67 AS Aortic Stenosis
- 68 AUC Area under curve
- 69 AVA Aortic Valve area
- 70 C-CT Cardiac computer tomography
- 71 DSE Dobutamine stress echocardiography
- 72 LV left ventricular
- 73 LVMi Left ventricular mass index
- 74 RWT Relative wall thickness
- 75 SVi Stroke volume indexed
- 76 Vmax Aortic valve peak velocity

77 While the diagnosis of severe aortic stenosis (AS) is straightforward when aortic valve area (AVA) is <1.0 cm^2 and transvalvular mean gradient is \geq 40 mmHg,¹ diagnosis may be more challenging when gradients are 78 79 low. When this occurs in the presence of reduced stroke volume (SV) and left ventricular ejection fraction 80 (LVEF)<50%, guidelines recommend the use of dobutamine stress echocardiography (DSE) to distinguish between true-severe –and pseudo-severe AS.²⁻⁴ However, only few data support a LVEF threshold of 50% as 81 most studies have tested DSE in patients with severely reduced LVEF. Furthermore, evidence suggests that 82 in AS LVEF may even be considered reduced already when less than 60%,^{2,5} explaining why some, advocate 83 DSE may provide diagnostic information even when LVEF >50%.⁶ However, all these studies are limited by 84 the lack of a clear gold-standard of assessing AS severity,^{7,8} and have thus largely been based on prognostic 85 data⁹ rather than objective measures for AS severity per se. This poses a potential problem as DSE findings 86 87 not being blinded for the clinicians, may have influenced decision making, potentially biasing the clinical end-point,¹⁰⁻¹² even more so as even moderate AS may be associated with a poor prognosis when LVEF is 88 reduced.13 89 90 Aortic valve calcification (AVC) assessed by cardiac computer tomography (C-CT) has recently emerged as an additional method of determining AS-severity.³ AVC has been demonstrated to clearly discriminate 91 between moderate and severe AS,¹⁴ and is associated with outcome.¹⁵ Accordingly, ESC and AHA/ACC 92

93 recommend the use of AVC to diagnose severe AS, in particular among patients with low-gradient AS.^{2, 3}

The purpose of this study was to examine the diagnostic accuracy of guideline recommendations for DSE in
low-gradient AS, in patents with a wide range of LVEF and to examine if an interaction between the
diagnostic accuracy of DSE and LVEF exist. Furthermore, we studied the safety and feasibility of DSE in

97 patients with LVEF>50%.

98

99 Methods

100 We identified patients aged \geq 18 years with low-gradient AS (aortic mean-gradient<40 mmHg and AVA<1.0 101 cm²) and stroke volume index (SV_i) \leq 35 mL/m² from two prospectively collected cohorts at Quebec Heart

and Lung Institute, Canada^{12, 16} and a prospective cohort collected at Odense University Hospital, Denmark
 between 2019 and 2022.

104 For this study, we excluded patients with missing DSE or C-CT data or with concomitant moderate or severe

105 valvular heart disease other than AS. Patients were stratified in three subgroups according to LVEF (LVEF

106 <35%, LVEF 35-50% and LVEF >50%) at the baseline evaluation which included a clinical examination,

107 transthoracic echocardiography and DSE.

108 Research was performed in accordance with the Declaration of Helsinki, and informed consent was

109 obtained according to approval by each institutional review board.

110

111 Echocardiography

Patients underwent a comprehensive transthoracic echocardiographic examination using commercially 112 available ultrasound systems in accordance with the American Society of Echocardiography guidelines^{17, 18} 113 114 with interpretation performed by experienced cardiologists. Doppler values were calculated as the average of three cardiac cycles for patients with sinus rhythm and five cycles for atrial fibrillation. LV outflow tract 115 116 diameter was measured in the parasternal long-axis view in early systole from the point of aortic cusp 117 insertion into the interventricular septum to the point of aortic cusp insertion into the intervalvular fibrosis. AVA was estimated by quantitative Doppler ultrasound using the continuity equation. Peak and mean flow 118 119 velocity across the valve were determined in the window where the highest velocity could be recorded using continuous wave Doppler with the cursor as parallel as possible with the flow across the valve. Peak 120 and mean transvalvular gradients were estimated using the modified Bernoulli equation.¹ LVEF was 121 determined by the Simpson biplane method. LV stroke volume was calculated using pulsed-wave Doppler 122 123 as the product of the LV outflow area and LV outflow tract time velocity integral and indexed for body 124 surface area (SVi). LV mass index was estimated using the Devereux formula.¹⁹ In men LV mass index >116 g/m^2 and in women, >104 g/m^2 were considered indicative of LV hypertrophy.²⁰ Relative wall thickness 125 (RWT) was calculated for assessment of LV geometry using the formula 2xposterior wall thickness/LV 126

127 internal diameter in diastole. Increased relative wall thickness was pre	esent when this ratio was>0.42. ²¹
--	---

- 128 Normal geometry was present when LV mass index and RWT were normal, concentric remodeling with
- 129 increased RWT and normal LV mass index, eccentric LV hypertrophy with increased LV mass index and
- 130 normal RWT, and concentric LV hypertrophy when both were increased.
- 131 Valvulo-arterial impedance was calculated using the formula (systolic blood pressure + mean aortic valve
- 132 pressure gradient)/SVi.²² Pulse pressure was measured as the difference between systolic and diastolic
- 133 blood pressure, and systemic arterial compliance was calculated as SVI/pulse pressure,²² Systemic vascular
- resistance was calculated as 80*(1/3*systolic blood pressure+2/3*diastolic blood pressure)/cardiac
- 135 output.²²
- 136

137 Dobutamine stress echocardiography

A comprehensive DSE was performed in all patients. Dobutamine infusion was initiated at a dose of 5 $\mu g/kg/min$ and increased every 3rd min to a maximal dosage of $20\mu g/kg/min$. DSE was terminated early if an adverse event occurred, if the patient became symptomatic during the examination, or if a mean gradient > 40 mmHg was recorded in patients with LVEF <50%. Contractile reserve was defined as an increase in SV_i exceeding 20%. We defined patients as still having a low-flow state if SV_i was \leq 35 mL/m²

143 despite DSE.

Three cardiac cycles were averaged for all measurements in patients with sinus rhythm, and five cardiac cycles were averaged for patients with atrial fibrillation. Echocardiographic measurements of aortic flow and LV were obtained at each stage. During DSE heart rate, systolic and diastolic blood pressure was recorded at each dose increment.

148

149 Cardiac computer tomography

All patients underwent a non-contrast C-CT with a tube potential at 120 kV. Operators blinded to patient
 clinical and echocardiographic data performed all MDCT analyses. The aortic valve was visualised in

152	multiple planes, and careful measurement section by section aimed to accurately distinguish contiguous
153	calcium in coronary arteries, mitral valve annulus or aortic wall. AVC score was assessed using the Agatston
154	method, and expressed in arbitrary units. We defined severe AS using the sex-specific thresholds
155	recommended by guidelines, AVC score ≥2000 AU in males, and ≥1200 AU in females on C-CT. ^{2, 3, 23}
156	
157	DSE safety end-points
158	Patients undergoing DSE were safety monitored for adverse events. Adverse events during DSE were
159	defined as new onset of complex ventricular arrhythmia, a rise in systolic blood pressure ≥200mmHg, a
160	decrease in systolic blood pressure <80 mmHg, LV outflow tract peak-flow velocity ≥ 2.0 m/sec or systolic
161	anterior motion of the mitral valve.
162	
163	Statistical analysis
164	Continuous variables were tested for normality with the Shapiro-Wilk test and are expressed as either
165	mean ± SD or median and interquartile range. Differences in values between groups were tested by 1-way
166	ANOVA. Categorical variables are expressed as number and percentages, and tested by the χ^2 exact test of
167	Fisher exact test when the expected value in any of the cells of a contingency table was below 5.
168	Time between C-CT and DSE, and AVC are presented as median and interquartile range, and differences
169	were tested using the Kruskal-Wallis test because of non-Gaussian distribution for these variables.
170	Correlations were obtained using Spearman rank test. For overall tests, a P value of <0.05 were considered
171	significant and 2-sided tests were used. Comparison of each method's predictive capability was performed
172	by comparing the C-statistic derived from the area under the receiver operating characteristic curves using
173	the generalized U-statistic as proposed by DeLong et al. ²⁴ Statistical analysis was performed with STATA/SE
174	V.17.0 (StataCorp, Texas, USA) software.
175	
176	

177 Results

We identified 635 patients with low-gradient AS, and excluded those with missing C-CT data (n=240), 178 missing DSE data (n=178), and AVA>1.0 cm² (n=8) or mean gradient>40 mmHg (n=1) leaving 221 patients 179 180 (n=150 Quebec Heart Institute, n=71 Odense University Hospital) in this study. Seventy-eight (35%) 181 presented with LVEF <35%, 67(30%) with LVEF 35-50%, and 76(34%) with LVEF >50%. DSE and C-CT were performed within a median timespan of 12 [1; 26] days, with no difference between groups (p=0.17). 182 183 Patients with LVEF >50% were more likely to be women, had less symptoms, and were less likely to have a 184 pacemaker or ICD-device (Table 1). Severe AS, as evaluated by AVC, was present among 102 (46%) patients 185 with no differences between groups, (55% vs 37% vs 46%, LVEF<35% LVEF 35-50%, LVEF>50% respectively, 186 p = 0.10). Patients with LVEF >50% presented with higher V_{max} (304±45 vs 302±43vs 324±37cm/s, p<0.01) 187 and mean gradient (22±7 vs 23±7 vs 25±6mmHg, p=0.03), despite similar AVA. 188 An inverse relationship was seen between LVEF and left ventricular diameter (r=-0.65, p<0.001) (table 1). 189 Patients with LVEF<35% had higher LVM_i and lower RWT than patients with LVEF>35%. These differences 190 translated to significant differences in geometric patterns with eccentric hypertrophy being the most 191 common pattern among patients with LVEF<35%, and patients with LVEF 35-50%, and normal geometry in patients with LVEF>50% (p<0.001) (Table 1). All patients had SV_i<35 ml/m², but a higher resting SV_i was 192 193 present in patients with LVEF >50% ($26\pm5vs 26\pm5vs 29\pm4mL/m^2$, p<0.01, Table 1). 194

195 Dobutamine stress echocardiography

DSE was performed without adverse symptoms in two-hundred-fifteen (97%) patients. However, in six patients DSE was discontinued prematurely due to adverse symptoms (n=1 systolic blood pressure>200 mmHg, n=1 angina, n=1 dyspnea=1, n=3 other discomfort) being most common among patients with LVEF>50% (0% vs 2% vs. 9%, p=0.04, LVEF<35%; LVEF 35-50% and LVEF>50% respectively). In contrast no ventricular arrhythmia during DSE were seen in patients with LVEF>50% while 8 patients with LVEF<50% (4 in LVEF<35% and 4 in LVEF 35-50%) experienced complex ventricular arrhythmia during DSE (Table 2).

202	During DSE, stroke volume increased uniformly with no between groups differences (15±12mL vs 13±13mL
203	vs 12 \pm 12mL, p=0.28), however more patients with reduced LVEF increased their SV _i \geq 20% (65% vs 49% vs
204	44%, p=0.03). One-hundred-twenty (56%) patients still had SV _i \leq 35 mL/m ² at the end of DSE evenly split
205	between LVEF subgroups (Table 3). Stroke volume increased unanimously regardless of a history of
206	coronary artery disease or intracardiac device, beta-blocker therapy or AS severity (Supplemental figure 1).
207	Despite similar systemic vascular resistance and valvulo-arterial impedance during baseline and
208	dobutamine infusion, patients with LVEF>35% experienced lower systemic arterial compliance than those
209	with LVEF<35% both at baseline and during DSE (0.56 \pm 0.21 vs 0.48 \pm 0.17 vs 0.50 \pm 0.14ml/m ² /mmHg, p=0.02,
210	LVEF<35%, LVEF 35-50%, LVEF>50% respectively).
211	
212	Classifying severe AS in the entire cohort

213 Receiver operating characteristic curves for DSE-derived mean gradient, V_{max} and AVA are provided in

Figure 2. C-statistics for the mean gradient (AUC=0.73) were non-significant higher than V_{max} (AUC=0.70)

but significantly higher than AVA (AUC=0.61) (p=0.01, Figure 2), with differences remaining non-significant

- 216 in a direct comparison between mean gradient and V_{max} after including AVA in both models (AUC 0.74 vs
- 217 0.72, p=0.12).

The optimal cut-off points for discriminating between severe and pseudo-severe-AS during DSE was
identified from ROC-curves; 34 mmHg, 389 cm/s and 0.9 cm² with a sensitivity and specificity of 75%/64%
vs 70%/63% vs 63%/55% when utilising these thresholds (mean gradient, V_{max} and AVA respectively) (Table
4). Applying either of the guideline specific thresholds; mean gradient > 40mmHg, V_{max} > 400cm/s or AVA
<1.0cm², lead to a sensitivity and specificity of 49%/78% vs 64%/66%, vs 41%/78%, respectively (Table 4).
Combining guideline recommendations for AVA and either mean gradient or V_{max} led to a sensitivity and
specificity of 54%/77% for the entire cohort.

225

226

227 Classifying severe AS according to LVEF subgroups.

- 228 Comparing the ability of DSE variables to predict severe AS demonstrated significant heterogeneity
- between LVEF subgroups. AVA displayed a rather uniform optimal cut-off between LVEF subgroups (1.0 cm²
- vs 0.9 cm² vs 0.8 cm², LVEF<35%, LVEF 35-50%, LVEF>50%, respectively) with similar c-statistics (AUC=0.68,
- vs AUC 0.62 vs 0.54, p=0.36, LVEF<35, LVEF35-50%, LVEF>50% respectively, Figure 3). In contrast, the
- association of both mean gradient and V_{max} with AS severity was more accurate in the LVEF<35% group
- 233 (Mean gradient; AUC=0.90 vs.0.67 vs 0.65, p=0.0007, V_{max}; AUC=0.90 vs 0.66 vs 0.60, p=0.0001, Figure 3),
- with different optimal cut-off points (30 vs 45 vs 37mmHg & 377 vs 430 vs 400cm/s, LVEF<35%, LVEF 35-
- 235 50%, LVEF>50%, respectively).
- 236 Using guideline thresholds for both AVA and either mean gradient or V_{max} led to a sensitivity and specificity
- 237 of 54%/93% vs 41%/78% vs 64%/63%, LVEF<35%, LVEF 35-50%, LVEF>50%, respectively (Figure 4). For all

patients with LVEF <50%, the sensitivity and specificity was 49%/84%.

- Optimal cutoff points were similar between LVEF subgroups, regardless of including center or flow-stateduring DSE.
- 241

242 Discussion:

243 In this study with prospectively enrolled patients with low-gradient AS undergoing DSE we demonstrate 244 four novel findings. 1) DSE is safe with few patients experiencing dobutamine associated complications in 245 patients with reduced as well as preserved LVEF. 2) DSE leads to a uniform increase in stroke volume in 246 patients with low gradient aortic stenosis regardless of baseline LVEF. 3) The transvalvular mean gradient and transvalvular peak-velocity during DSE outperformed AVA in diagnosing severe AS adjudicated with C-247 248 CT aortic valve calcium score. However, mean gradient was associated with a lower sensitivity but higher 249 specificity than V_{max}. Utilizing the guideline recommendations of combining transvalvular gradients with 250 AVA resulted in a specific but non-sensitive discrimination between severe and pseudo-severe AS in 251 patients with LVEF<50%, highlighting that a large proportion of patients with high AVC are labeled as

252	pseudo-severe AS based on DSE findings. This suggests that there is a discrepancy between the guideline
253	recommended thresholds of DSE and CT indices of severe AS. 4) Although AVA during DSE provided
254	modest, but similar information regardless of LVEF, with a rather uniform optimal cut-off of 0.9 cm ² , both
255	transvalvular mean-gradient and peak-velocity demonstrated important heterogeneity with outstanding
256	discrimination in patients with LVEF<35% while only modest in those with LVEF>35%. In addition, the
257	optimal discriminatory threshold was markedly different between LVEF groups with a mean-gradient 30
258	mmHg being the best cut-off in patients with LVEF<35%, and 40 mmHg in those with LVEF>35%. The later
259	suggests that discrepancies exist between guidelines proposed thresholds for DSE and CT in the assessment
260	of severe AS and reduced LVEF.

261

262 LOW-GRADIENT AS AND DSE IN CURRENT GUIDELINES

While for decades it has been accepted that severe AS may occur despite low-gradients, when LVEF is
reduced,²⁵ it was not until the seminal paper by Hachicha and colleagues²⁶ that it became clear that this
could also be the case when LVEF>50%. Regardless of LVEF, low-gradient AS raises the diagnostic
conundrum of differentiating between severe- and pseudo-severe AS.
Currently, guidelines distinguish between patients according to stroke volume. Patients with low-gradient

268 AS under normal-flow conditions $(SV_i>35 \text{ ml/m}^2)$ are thought as having moderate AS., while further testing is required in patients with SV_i<35 ml/m²to determine AS severity. For patients with LVEF<50%, guidelines 269 recommend the use of DSE in order to increase flow and demonstrate high-gradients with a reduced AVA.^{2,} 270 ³ This strategy has been recommended since deFilippi and colleagues suggested it in 1995,²⁷ and Monin et 271 al. in 2 subsequent larger populations tested the possible impact of DSE on outcome.^{10, 11} In the first study 272 273 including forty-five patients with low-gradient AS and LVEF<30%, DSE with a mean dosage of 9 µg/kg/min 274 lead to an increase in stroke volume, with 71% demonstrating contractile reserve with no adverse events. 275 Despite similar baseline characteristics, patients with contractile reserve experienced better outcome, in

particular if undergoing surgery.¹⁰ These findings were corroborated in a subsequent paper with a larger
sample size including 136 patients with low-gradient AS patients and LVEF<35%.¹¹

278 In line with these studies, we concordantly demonstrate that ~2/3 of patients with LVEF<35% had

279 contractile reserve, but as a novel finding show a lower rate of contractile reserve among patients with

- 280 LVEF>35%. Although this could counterintuitively be interpreted as patients with higher baseline LVEF
- 281 having a poorer ability to increase their contractile state, we speculate this rather reflects differences in LV-
- geometry, and baseline SV_i between groups. While reduced stroke volume in patients with LVEF<35% is the
- 283 consequence of poor contractility, patients with LVEF>50% predominantly have a reduced stroke volume
- due to concentric LV remodeling that leads to small cavities and impeding normal stroke volume despite
- preserved LVEF.²⁸ Accordingly, the combination of smaller cavities combined with a higher baseline SVi in

patients with LVEF>50% challenges a SV_i increase > 20% as a criterion for contractile reserve. Thusly,

287 caution should be taken when interpreting contractile reserve without regards to LVEF. This may pose a

288 potential problem as guidelines recommend the use of DSE in patients with LVEF<50% while DSE, and

289 contractile reserve, has mainly been studied in patients with LVEF<35%. ⁷⁻¹²

290

291 C-CT RECOMMENDATIONS IN CURRENT GUIDELINES

292 A potential limitation of DSE is that AS severity may be challenging to grade when flow does not increase during DSE. In this setting, Cueff and colleagues demonstrated that C-CT derived AVC using a cut-off 1650 293 AU was able to distinguish severe from non-severe AS when LVEF<40%.²⁹ Since, it has been demonstrated 294 295 that the impact of calcification on AS severity is largely affected by sex, as females demonstrate a steeper 296 association between calcium load and gradient than males and will experience severe AS despite less calcium.³⁰ Accordingly, it has been demonstrated that AVC has different sex-specific thresholds for men and 297 298 women for the same echocardiographic measurement of AS-severity.^{23, 31} Consequently, AVC has been 299 implemented in the current ESC and AHA/ACC guidelines as a tool to differentiate between moderate and 300 severe AS and is recommended in patients with low-gradient AS without contractile reserve on DSE or

301 when LVEF>50%. It is thus interesting that among patients with LVEF<50% and severe AS ascertained by C-

302 CT, 23% were labeled as having pseudo-severe AS when combining DSE gradients and AVA.

303 These discrepancies imply that a diagnosis of severe AS is more likely if we use C-CT assessed AVC rather

than DSE data. Thus, patients with LVEF <35% and contractile reserve are less likely to be labeled as severe

305 AS, based solely on DSE response, than patients without contractile reserve where determination of AS-

306 severity relies on AVC.

As a consequence, it seems that while current DSE recommended thresholds are rather specific, they are
 also non-sensitive when compared to C-CT. This naturally raises the question of why the current thresholds
 have been chosen.

310

311 THRESHOLDS IN CURRENT GUIDELINES

312 While most DSE studies in low-gradient AS have used the same thresholds for AS severity as in normal flow, 313 confirmation of AS severity has solely been based on either patient outcome or surgeons' evaluation during surgery as the indication of AS severity. ^{10, 11} In these studies, the decision of surgery was not blinded for 314 315 DSE-response, and as no gold standard for severe AS existed outcome was chosen. The latter may pose a 316 particular problem as it recently has become evident that even moderate AS may have an impact on 317 outcome in patients with LVEF<50%.¹³ 318 Indeed, a recent study by Annabi and colleagues intended to identify thresholds of severe AS based with DSE. However, confirmation was only possible in 87 of 186 patients, and only in 25 ascertained by CT.³² 319 320 Thus, our study is the first to compare the response of DSE with AS severity ascertained by C-CT.

321 Accordingly, it is interesting that while AVA demonstrated a rather uniform cut-off between LVEF-

322 subgroups, both transvalvular mean gradient and transvalvular peak-velocity showed higher accuracy in

323 patients with LVEF <35% with an optimal cut-off points of 30mmHg for transvalvular mean gradient and

324 377 cm/s for transvalvular peak-velocity.

325	These findings are in accordance with a previous paper by Nishimura and colleagues reporting that under
326	DSE, an invasively measured gradient of <30 mmHg correlated with severe AS. ³³ In line with this, Annabi et
327	al. found guideline DSE thresholds to have limited value in predicting stenosis severity, and demonstrated
328	that lowering the cut-off point for transvalvular mean gradient to either 35 mmHg or 30 mmHg improved
329	the diagnostic accuracy of DSE. ³²
330	A possible explanation to our finding could be that despite dobutamine raising stroke volume in most
331	patients, almost half still experience a low-flow condition after dobutamine infusion suggesting that a lower
332	gradient would be expected than during normal flow. Furthermore, while dobutamine has a positive
333	inotropic effect on the heart stimulating $eta 1$ receptors, the effects on the $lpha$ receptors may also alter
334	vascular resistance, changing the ventriculo-arterial coupling and eventually lowering the transvalvular
335	gradients. ³⁴ Suggestive of this, we demonstrated different systemic arterial compliance between LVEF
336	groups.
337	Finally it is also possible that inconsistencies exist between gradients and AVA as a consequence of
338	discrepancies also described in patients with normal systolic LV function. ³⁵
339	
340	Study limitations:
341	Assessment of AS severity is challenging as severity can be graded based on a wide range of variables with
342	no clear gold standard. In this study, we used C-CT assessed AVC as the reference for adjudication of AS
343	severity. Different concerns can been raised regarding this choice as 1) AVC does not quantify fibrotic
344	tissue, which might play an important role in the development of low-gradient AS, ^{14, 30} or in bicuspid valves;
345	2) the current thresholds are derived from patients with concordant AS and have not been validated in low-
346	gradient AS patients, and 3) that reproducibility of AVC may be challenging. However, the Agatston method
347	is a well-established marker of anatomic severity that has demonstrated to correlated with valve severity
348	on explanted valves, ³⁰ AS hemodynamic severity measured by Doppler echocardiography, ^{29, 36} and clinical

349 outcomes.^{15, 31}

350	Furthermore the reproducibility of AVC has been questioned. In our study, the measurement of AVC was
351	done separately in each institution, but was standardized between centers and demonstrated excellent
352	reproducibility.
353	While echocardiographic measurements were performed by experienced users, newer studies show, that in
354	patients with atrial fibrillation the maximum peak velocity and mean gradient might be a more precise
355	measurement for AS severity instead of an averaged peak velocity or mean gradient, when compared to C-
356	CT. ³⁷
357	
358	Conclusion:
359	The use of DSE is safe and leads to a uniform increase in stroke volume in patients with low gradient AS
360	regardless of baseline LVEF. However, the association between DSE gradients and AS severity assessed by
361	C-CT demonstrates important heterogeneity, with highest accuracy in patients with LVEF<35% but limited
362	diagnostic yield when LVEF≥35%, and with different optimal diagnostic thresholds.
363	
364	Acknowledgements:
365	OPEN, Open Patient data Explorative Network, Odense University Hospital, Region of Southern Denmark.
366	
367	Sources of funding:
368	This work was supported by research grants from the Region of Southern Denmark and the University of
369	Southern Denmark.
370	
371	Disclosure:
372	None.

373 Figure Legends

- Figure 1: Consort flowchart of patient inclusion. Consort Flowchart showing the process of inclusion and
 exclusion of patients.
- - AS: aortic stenosis, AVA: aortic valve area, C-CT: Cardiac Computer tomography, DSE: dobutamine stress
 - 377 echocardiography, LVEF: left ventricular ejection fraction SV_i: stoke volume indexed.
 - 378 Figure 2: Receiver-Operating Characteristic to identify severe AS in the entire cohort. Receiver-Operating
 - 379 Characteristic to identify severe aortic stenosis (AS) in the entire cohort of 221 patients with low-gradient
 - AS (mean gradient <40 mmHg and aortic valve area <1.0 cm²) and stroke volume index \leq 35 mL/m²
 - 381 according to (A) mean gradient, peak velocity and aortic valve area, (B) Combination of mean gradient +
 - 382 aortic valve area and peak velocity + aortic valve area against computed tomography aortic valve
 - 383 calcification.
 - 384 MG: mean gradient, V_{max}: peak velocity, AVA: aortic valve area, AUC: area under the curve, DSE:
 - 385 Dobutamine Stress Echocardiography.
 - 386 Figure 3: Receiver-Operating Characteristic to identify severe AS in LVEF subgroups. Receiver-Operating
 - 387 Characteristic to identify severe aortic stenosis (AS) in LVEF subgroups; LVEF <35%, 35-50% and >50%
 - 388 respectively, according to (A) mean gradient, (B) peak velocity, and (C) aortic valve area against computed
 - 389 tomography aortic valve calcification.
 - 390 LVEF: left ventricular ejection fraction, AUC: area under the curve.
 - **Figure 4: Pseudo-severe and True-severe AS in LVEF subgroups.** Scatterplots for LVEF subgroups; LVEF
 - 392 <35%, 35-50% and >50% respectively. Green represents Pseudo-severe aortic stenosis (AS) and Blue True-
 - 393 severe AS determined by aortic valve calcification. Dashed lines represents guideline cut-offs for mean
 - 394 gradient (40 mmHg) and aortic valve area (>1.0cm²); (**A**) LVEF <35%, (**B**) LVEF 35-50%, (**C**) LVEF >50%. (**D**)
 - 395 Sensitivity and specificity for severe AS according to guideline cut-offs for DSE for each LVEF subgroups;
 - 396 LVEF <35%, 35-50% and >50% respectively.

397 LVEF: left ventricular ejection fraction, DSE: dobutamine stress echocardiography, AVA: aortic valve area,

398 AS: aortic stenosis.

399 Table 1: Baseline Characteristics

	LVEF <35%	LVEF 35-50%	LVEF >50%	P-value
	(n=78)	(n=67)	(n=76)	
Age (years)	77 ±8	76 ±8	76 ±8	0.56
Female sex	11 (14)	25 (37)	35 (46)	<0.001
Body surface area (m ²)	1.9 ±0.2	1.9 ±0.2	1.9 ±0.2	0.28
Heart rate, rest (bpm)	72 ±14	75 ±16	74 ±12	0.64
NYHA class III-IV	46 (65)	26 (46)	15 (24)	<0.001
Renal failure (eGFR <30)	10 (13)	4 (6)	5 (7)	0.24
Diabetes	31 (40)	32 (48)	22 (29)	0.02
Hypertension	63 (81)	48 (72)	57 (75)	0.38
Coronary artery disease	36 (46)	25 (37)	29 (38)	0.65
Never smoking	31 (47)	23 (46)	31 (48)	1.00
Pacemaker or ICD	24 (31)	8 (12)	15 (20)	0.02
Cardiac-CT data				
		1634	1831	
AVC in males (AU)	2183 [1326;3170]	[1107;2376]	[1441;2661]	0.07
		4000 [600 4000]	1067	0.00
AVC In females (AU)	8/5 [607;1624]	1088 [632;1989]	[485;1827]	0.82
Severe AS on CI	43 (55)	25 (37)	34 (45)	0.10
Echocardiographic data	204 - 45		224 : 27	0.004
Aortic V _{max} (cm/sec)	304 ±45	302 ±43	324 ±37	<0.001
Aortic Mean Gradient (mmHg)	22.3 ±7.0	23.0 ± 7.1	25.1 ±6.1	0.03
Aortic Valve Area (cm ⁻)	0.76 ±0.13	0.//±0.14	0.73 ±0.13	0.23
Dimensionless index	0.20 ±0.04	0.23 ±0.04	0.24 ±0.05	< 0.001
LV ejection fraction (%)	26 ±6	41 ±4	60 ±6	< 0.001
Stroke Volume (mL)	49.3 ±11.5	49.9 ±10.0	54.3 ±9.3	0.01
Stoke Volume Index (mL/m ²)	25.6 ±5.4	26.2 ±4.9	28.9 ±4.4	<0.001
Interventricular septal thickness (mm)	11.3 ±2.3	11.3 ±2.3	11.8 ±2.5	0.42
LV end-diastolic diameter (mm)	59.5 ±6.7	53.8 ±5.3	48.1 ±7.0	<0.001
Posterior wall Thickness (mm)	9.6 ±1.8	9.8 ±1.5	9.9 ±2.6	0.67
Left ventricular mass index (g/m ²)	139 ±36	120±29	104 ±31	<0.001
Relative wall thickness	0.33 ±0.08	0.37 ±0.07	0.41 ±0.11	<0.001
LV remodeling pattern				
Normal	19 (24)	23 (34)	28 (37)	
Concentric Hypertrophy	21 (27)	12 (18)	15 (20)	
Concentric Remodeling	0 (0)	3 (5)	19 (25)	
Eccentric Hypertrophy	38 (49)	29 (43)	14 (18)	<0.001

Abbreviations: AS aortic stenosis; AVC Aortic valve calcification; eGFR estimated glomerular filtration rate;
 ICD intracardiac defibrillator; LV left ventricular, NYHA: New York Heart Association; V_{max}: peak velocity.

⁴⁰²

	LVEF <35%	LVEF 35-50%	LVEF >50%	
	(n=78)	(n=67)	(n=76)	P-value
Max systolic BP during DSE (mmHg)	133 ±27	141 ±21	149 ±23	<0.001
Systolic BP during max DSE dose (mmHg)	130 ±27	134 ±21	142 ±23	0.03
Systolic BP <80mmHg	0 (0)	0 (0)	1 (1)	0.38
Systolic BP >200mmHg	1 (1)	0 (0)	2 (3)	0.40
DSE stopped because of adverse symptoms	0 (.0)	1 (2)	5 (7)	0.03
Chest pain	1 (1)	2 (3)	2 (3)	0.76
Ischemia on ECG	0 (0)	0 (0)	0 (0)	0.99
Newly onset SVT	1 (1)	1 (2)	1 (1)	0.99
Complex ventricular arrhythmia	4 (5)	4 (6)	0 (0)	0.11

404 Table 2: Safety parameters during dobutamine stress echocardiography

405 Abbreviations: BP blood pressure; DSE dobutamine stress echocardiography; ECG electrocardiogram; SVT

406 supraventricular tachycardia.

408 Table 3: Dobutamine stress echocardiograhic parameters

	LVEF <35%	LVEF 35-50%	LVEF >50%	P-value
	(n=78)	(n=67)	(n=76)	
Hemodynamic data				
Systolic BP, rest (mmHg)	123 ±21	129 ±18	137 ±21	<0.001
Diastolic BP, rest (mmHg)	72 ±12	71 ±10	75 ±13	0.08
Systolic BP during max DSE dose (mmHg)	130 ±27	134 ±21	142 ±23	0.03
Diastolic BP during max DSE dose (mmHg)	67 ±14	67 ±13	69 ±12	0.68
BP pressure change (mmHg)	10 ±23	9 ±22	9 ±20	0.97
Max heart rate during DSE (bpm)	93 ±18	103 ±25	103 ±24	0.08
Change in heart rate (bpm)	25 ±20	21 ±15	24 ±19	0.78
Zva, rest (mmHg/mL/m ²)	5.85 ±1.47	6.00 ±1.27	5.76 ±1.17	0.55
Zva, DSE (mmHg/mL/m ²)	5.01 ±1.41	5.48 ±1.45	5.38 ±1.28	0.24
Zva, diff. (mmHg/mL/m ²)	1.12 ±0.95	1.10 ±0.73	0.93 ±0.63	0.39
Systemic Arterial Compliance, rest (Units)	0.56 ±0.21	0.48 ±0.17	0.50 ±0.14	0.02
Systemic Arterial Compliance, DSE (Units)	0.60 ±0.21	0.50 ±0.17	0.51 ±0.18	0.02
Systemic Arterial Compliance, diff. (Units)	0.17 ±0.11	0.12 ±0.12	0.11 ±0.10	0.02
SVR, rest (mmHg/L/min)	1239 ±451	1241 ±395	1221 ±380	0.97
SVR, DSE (mmHg/L/min)	1209 ±562	1269 ±389	1228 ±375	0.85
SVR, diff. (mmHg/L/min)	173 ±177	199 ±164	144 ±131	0.28
Stroke Volume, DSE (mL)	64.6 ±15.5	63.3 ±16.4	65.6 ±15.6	0.68
Low-Flow(<35ml/m ²) despite DSE	42 (58)	41 (62)	37 (49)	0.29
Change in SV (mL)	14.7 ±11.5	13.1 ±12.5	11.5 ±11.8	0.28
Change in SVi >20%	47 (65)	32 (49)	33 (44)	0.03
Aortic V _{max} , DSE (cm/sec)	377 ±55	378 ±58	405 ±47	<0.001
Change in V _{max} (cm/sec)	70 ±35	76 ±39	82 ±33	0.14
Aortic Mean Gradient, DSE (mmHg)	32.7 ±10.1	34.2 ±11.5	38.7 ±9.9	<0.001
Change in Mean Gradient (mmHg)	10.6 ±5.7	11.6 ±6.7	13.7 ±6.5	0.01
Aortic Valve Area, DSE (cm ²)	0.94 ±0.28	0.97 ±0.33	0.91 ±0.21	0.52
Change in AVA (cm ²)	0.19 ±0.23	0.21 ±0.30	0.19 ±0.15	0.86
DSE Dimensionless index	0.24 ±0.05	0.28 ±0.06	0.30 ±0.07	<0.001

409 Abbreviations: AVA aortic valve area BP blood pressure; DSE dobutamine stress echocardiography; SV

410 stroke volume; SV_i stroke volume indexed; SVR Systemic Vascular Resistance; V_{max} peak velocity; Zva

411 Valvulo-arterial Impedance .

412 Table 4: Diagnostic accuracy of dobutamine stress echocardiography in differentiating severe from

413 pseudo-severe AS

	Optimal cut	-off points		Gu	ideline recor	nmendations	6	
Marker	Sensitivity	Specificity	CC	Marker	Sensitivity	Specificity	CC	
MG	75%	64%	69%	MG	49%	78%	65%	
(≥34mmHg)				(≥40mmHg)				
V_{max}	70%	63%	66%	V_{max}	64%	66%	65%	
(≥389cm/s)				(≥400cm/s)				
AVA	63%	55%	60%	AVA	41%	78%	58%	
(<0.9cm ²)				(<1.0cm ²)				
Combined	48%	87%	67%	Combined	50%	67%	67%	
(for LVEF				(for LVEF				
<50%)				<50%)				

414 **Abbreviations:** AVA aortic valve area; CC correct classification; MG mean gradient.

415 Figure 1



427 Figure 2



429 Figure 3





430

432 Figure 4



436 Central Illustration



Stroke volume index according to AS-severity by C-CT LVEF <35%



LVEF <35%						
Marker	Sensitivity	Specificity	CC			
MG (≥30 mmHg)	91%	80%	86%			
Vmax (≥377 cm/s)	83%	87%	85%			
AVA(<1.0 cm2)	55%	84%	72%			
Combined	73%	90%	80%			

--- MG, AUC: 0.90 --- AVA, AUC: 0.68 - Vmax, AUC: 0.90





sitivity

44%

46%

61%

27%

(<0.9cm2)

Specificity

75%

73%

59%

71%

93%

90%

55%

95%



Stroke volume index according to AS-severity by C-CT LVEF >50%





LVEF >50%			
Marker	Sensitivity	Specificity	CC
MG (≥37 mmHg)	76%	60%	67%
Vmax (≥400 cm/s)	71%	50%	59%
AVA(<0.8cm2)	78%	30%	57%
Combined	30%	78%	69%

Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, lung B, Otto CM,
 Pellikka PA and Quinones M. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations
 for clinical practice. *J Am Soc Echocardiogr*. 2009;22:1-23.

441 2. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, 3rd, Gentile F, Jneid H, Krieger

442 EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM, 3rd, Thompson A and Toly C. 2020 ACC/AHA

443 Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of

444 the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice

445 Guidelines. *Circulation*. 2021;143:e35-e71.

446 3. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi

L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Juni P, Pierard L,

448 Prendergast BD, Sadaba JR, Tribouilloy C, Wojakowski W and Group EESD. 2021 ESC/EACTS Guidelines for

the management of valvular heart disease. *European heart journal*. 2022;43:561-632.

450 4. Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R, Edvardsen T, Garbi M,

451 Ha JW, Kane GC, Kreeger J, Mertens L, Pibarot P, Picano E, Ryan T, Tsutsui JM and Varga A. The Clinical Use

452 of Stress Echocardiography in Non-Ischaemic Heart Disease: Recommendations from the European

453 Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc

454 *Echocardiogr*. 2017;30:101-138.

5. Dahl JS, Eleid MF, Michelena HI, Scott CG, Suri RM, Schaff HV and Pellikka PA. Effect of left
ventricular ejection fraction on postoperative outcome in patients with severe aortic stenosis undergoing
aortic valve replacement. *Circ Cardiovasc Imaging*. 2015;8.

Clavel MA, Ennezat PV, Marechaux S, Dumesnil JG, Capoulade R, Hachicha Z, Mathieu P,
 Bellouin A, Bergeron S, Meimoun P, Arsenault M, Le Tourneau T, Pasquet A, Couture C and Pibarot P. Stress
 echocardiography to assess stenosis severity and predict outcome in patients with paradoxical low-flow,

low-gradient aortic stenosis and preserved LVEF. JACC Cardiovascular imaging. 2013;6:175-83.

462 7. Quere JP, Monin JL, Levy F, Petit H, Baleynaud S, Chauvel C, Pop C, Ohlmann P, Lelguen C,

- 463 Dehant P, Gueret P and Tribouilloy C. Influence of preoperative left ventricular contractile reserve on
- 464 postoperative ejection fraction in low-gradient aortic stenosis. *Circulation*. 2006;113:1738-44.
- 465 8. Tribouilloy C, Levy F, Rusinaru D, Gueret P, Petit-Eisenmann H, Baleynaud S, Jobic Y, Adams

466 C, Lelong B, Pasquet A, Chauvel C, Metz D, Quere JP and Monin JL. Outcome after aortic valve replacement

467 for low-flow/low-gradient aortic stenosis without contractile reserve on dobutamine stress

468 echocardiography. J Am Coll Cardiol. 2009;53:1865-73.

469 9. Clavel MA, Fuchs C, Burwash IG, Mundigler G, Dumesnil JG, Baumgartner H, Bergler-Klein J,

470 Beanlands RS, Mathieu P, Magne J and Pibarot P. Predictors of outcomes in low-flow, low-gradient aortic

471 stenosis: results of the multicenter TOPAS Study. *Circulation*. 2008;118:S234-42.

472 10. Monin JL, Monchi M, Gest V, Duval-Moulin AM, Dubois-Rande JL and Gueret P. Aortic

473 stenosis with severe left ventricular dysfunction and low transvalvular pressure gradients: risk stratification

474 by low-dose dobutamine echocardiography. *J Am Coll Cardiol*. 2001;37:2101-7.

475 11. Monin JL, Quere JP, Monchi M, Petit H, Baleynaud S, Chauvel C, Pop C, Ohlmann P, Lelguen

476 C, Dehant P, Tribouilloy C and Gueret P. Low-gradient aortic stenosis: operative risk stratification and

477 predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. *Circulation*.

478 2003;108:319-24.

479 12. Blais C, Burwash IG, Mundigler G, Dumesnil JG, Loho N, Rader F, Baumgartner H, Beanlands

480 RS, Chayer B, Kadem L, Garcia D, Durand LG and Pibarot P. Projected valve area at normal flow rate

481 improves the assessment of stenosis severity in patients with low-flow, low-gradient aortic stenosis: the

482 multicenter TOPAS (Truly or Pseudo-Severe Aortic Stenosis) study. *Circulation*. 2006;113:711-21.

483 13. Coisne A, Scotti A, Latib A, Montaigne D, Ho EC, Ludwig S, Modine T, Genereux P, Bax JJ, Leon

484 MB, Bauters C and Granada JF. Impact of Moderate Aortic Stenosis on Long-Term Clinical Outcomes: A

485 Systematic Review and Meta-Analysis. *JACC Cardiovasc Interv*. 2022;15:1664-1674.

Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf J, Araoz PA, Michelena HI,
Cueff C, Larose E, Capoulade R, Vahanian A and Enriquez-Sarano M. The complex nature of discordant

488 severe calcified aortic valve disease grading: new insights from combined Doppler echocardiographic and

- 489 computed tomographic study. J Am Coll Cardiol. 2013;62:2329-38.
- 490 15. Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, Aggarval S, Araoz PA,
- 491 Michelena HI, Cueff C, Larose E, Miller JD, Vahanian A and Enriquez-Sarano M. Impact of aortic valve
- 492 calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international
- 493 registry study. J Am Coll Cardiol. 2014;64:1202-13.
- 494 16. Bienjonetti-Boudreau D, Fleury MA, Voisine M, Paquin A, Chouinard I, Tailleur M, Duval R,

495 Magnan PO, Beaudoin J, Salaun E and Clavel MA. Impact of sex on the management and outcome of aortic

- 496 stenosis patients. *Eur Heart J.* 2021;42:2683-2691.
- 497 17. Barreiro CJ, Patel ND, Fitton TP, Williams JA, Bonde PN, Chan V, Alejo DE, Gott VL and
- 498 Baumgartner WA. Aortic valve replacement and concomitant mitral valve regurgitation in the elderly:

impact on survival and functional outcome. *Circulation*. 2005;112:1443-7.

500 18. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E,

501 Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang

502 W and Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an

503 update from the American Society of Echocardiography and the European Association of Cardiovascular

504 Imaging. *European heart journal cardiovascular Imaging*. 2015;16:233-70.

- 505 19. Devereux RB, Casale PN, Kligfield P, Eisenberg RR, Miller D, Campo E and Alonso DR.
- 506 Performance of primary and derived M-mode echocardiographic measurements for detection of left
- 507 ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral
- regurgitation and dilated cardiomyopathy. *AmJCardiol*. 1986;57:1388-1393.

50920.Devereux RB, Dahlof B, Levy D and Pfeffer MA. Comparison of enalapril versus nifedipine to510decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). AmJCardiol.

511 1996;78:61-65.

512 21. Ganau A, Devereux RB, Roman MJ, de SG, Pickering TG, Saba PS, Vargiu P, Simongini I and

Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension.

514 JAmCollCardiol. 1992;19:1550-1558.

515 22. Briand M, Dumesnil JG, Kadem L, Tongue AG, Rieu R, Garcia D and Pibarot P. Reduced

516 systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic

517 stenosis: implications for diagnosis and treatment. *JAmCollCardiol*. 2005;46:291-298.

518 23. Aggarwal SR, Clavel MA, Messika-Zeitoun D, Cueff C, Malouf J, Araoz PA, Mankad R,

519 Michelena H, Vahanian A and Enriquez-Sarano M. Sex differences in aortic valve calcification measured by

520 multidetector computed tomography in aortic stenosis. *Circ Cardiovasc Imaging*. 2013;6:40-7.

521 24. DeLong ER, DeLong DM and Clarke-Pearson DL. Comparing the areas under two or more

522 correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*. 1988;44:837-

523 845.

524 25. Carabello BA, Green LH, Grossman W, Cohn LH, Koster JK and Collins JJ, Jr. Hemodynamic
525 determinants of prognosis of aortic valve replacement in critical aortic stenosis and advanced congestive
526 heart failure. *Circulation*. 1980;62:42-48.

527 26. Hachicha Z, Dumesnil JG, Bogaty P and Pibarot P. Paradoxical low-flow, low-gradient severe
528 aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival.
529 *Circulation*. 2007;115:2856-2864.

deFilippi CR, Willett DL, Brickner ME, Appleton CP, Yancy CW, Eichhorn EJ and Grayburn PA.
Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic
stenosis in patients with depressed left ventricular function and low transvalvular gradients. *Am J Cardiol.*1995;75:191-4.

534 28. Dahl JS, Eleid MF, Pislaru SV, Scott CG, Connolly HM and Pellikka PA. Development of 535 paradoxical low-flow, low-gradient severe aortic stenosis. *Heart*. 2015;101:1015-23.

536 29. Cueff C, Serfaty JM, Cimadevilla C, Laissy JP, Himbert D, Tubach F, Duval X, Iung B, Enriquez-

537 Sarano M, Vahanian A and Messika-Zeitoun D. Measurement of aortic valve calcification using multislice

538 computed tomography: correlation with haemodynamic severity of aortic stenosis and clinical implication

for patients with low ejection fraction. *Heart*. 2011;97:721-6.

540 30. Simard L, Cote N, Dagenais F, Mathieu P, Couture C, Trahan S, Bosse Y, Mohammadi S, Page

541 S, Joubert P and Clavel MA. Sex-Related Discordance Between Aortic Valve Calcification and Hemodynamic

542 Severity of Aortic Stenosis: Is Valvular Fibrosis the Explanation? *Circ Res.* 2017;120:681-691.

543 31. Pawade T, Clavel MA, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L, Renard C, Gun M, Jenkins

544 WSA, Macron L, Sechrist JW, Lacomis JM, Nguyen V, Galian Gay L, Cuellar Calabria H, Ntalas I, Cartlidge

545 TRG, Prendergast B, Rajani R, Evangelista A, Cavalcante JL, Newby DE, Pibarot P, Messika Zeitoun D and

546 Dweck MR. Computed Tomography Aortic Valve Calcium Scoring in Patients With Aortic Stenosis. Circ

547 *Cardiovasc Imaging*. 2018;11:e007146.

548 32. Annabi MS, Touboul E, Dahou A, Burwash IG, Bergler-Klein J, Enriquez-Sarano M, Orwat S,

549 Baumgartner H, Mascherbauer J, Mundigler G, Cavalcante JL, Larose E, Pibarot P and Clavel MA.

Dobutamine Stress Echocardiography for Management of Low-Flow, Low-Gradient Aortic Stenosis. *J Am Coll Cardiol.* 2018;71:475-485.

552 33. Nishimura RA, Grantham JA, Connolly HM, Schaff HV, Higano ST and Holmes DR, Jr. Low-553 output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function: the clinical 554 utility of the dobutamine challenge in the catheterization laboratory. *Circulation*. 2002;106:809-13.

Solution
Sol

558	35.	Minners J, Allgeier M, Gohlke-Baerwolf C, Kienzle RP, Neumann FJ and Jander N.	
559	Inconsistencies of echocardiographic criteria for the grading of aortic valve stenosis. European heart		
560	journal. 2008;29:1043-8.		
561	36.	Messika-Zeitoun D, Aubry MC, Detaint D, Bielak LF, Peyser PA, Sheedy PF, Turner ST, Breen	
562	JF, Scott C, Tajik AJ and Enriquez-Sarano M. Evaluation and clinical implications of aortic valve calcificatio		
563	measured by electron-beam computed tomography. Circulation. 2004;110:356-62.		
564	37.	Alkurashi AK, Pislaru SV, Thaden JJ, Collins JD, Foley TA, Greason KL, Eleid MF, Sandhu GS,	

- Alkhouli MA, Asirvatham SJ, Cha YM, Williamson EE, Crestanello JA, Pellikka PA, Oh JK and Nkomo VT.
- 566 Doppler Mean Gradient Is Discordant to Aortic Valve Calcium Scores in Patients with Atrial Fibrillation
- 567 Undergoing Transcatheter Aortic Valve Replacement. *J Am Soc Echocardiogr*. 2022;35:116-123.